Evidence map›Paper›PMID 35427527›Full record

ArticleThe Lancet. Global health2022

Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study.

Scott A Nabity, Kelvin Mponda, Steve Gutreuter, Diya Surie, Suzgo B Zimba, Laphiod Chisuwo, Allison Moffitt, Anne M Williams, Andrea J Sharma, Rebekah E Marshall and 29 more

Open access · goldAbstract read
In one paragraph

Article in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Reframing Micronutrient Deficiencies for Modern times: A Review.Journal of general internal medicine · 2025
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

39 authors at 10 institutions in 2 countries.

Scott A NabityDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: hjq5@cdc.gov.
Kelvin MpondaDepartment of Medicine, Kamuzu University of Health Sciences, Blantyre, Malawi.
Steve GutreuterDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Diya SurieDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Suzgo B ZimbaElizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
Laphiod ChisuwoNational Public Health Reference Laboratory, Public Health Institute of Malawi, Lilongwe, Malawi.
Allison MoffittDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Anne M WilliamsNational Center for Chronic Disease Prevention and Health Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA; McKing Consulting Corporation, Atlanta, GA, USA.
Andrea J SharmaNational Center for Chronic Disease Prevention and Health Promotion, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Rebekah E MarshallDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Mabvuto J ChiwaulaNational Public Health Reference Laboratory, Public Health Institute of Malawi, Lilongwe, Malawi.
Robin da SilvaDepartment of Food Science and Human Nutrition, University of Florida, Gainesville, FL, USA.
Tapiwa KumwendaLighthouse Trust, Lilongwe, Malawi.
Lloyd ChilikutaliElizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
Shallom MwamaleElizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
Esther NagoliDepartment of Clinical Services, Malawi Ministry of Health, Lilongwe, Malawi.
Gerald MwenyeheriElizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
Dingase NgongondaDepartment of Clinical Services, Malawi Ministry of Health, Lilongwe, Malawi.
Esther KaundaDepartment of Clinical Services, Malawi Ministry of Health, Lilongwe, Malawi.
Fredrick MtotoDepartment of Clinical Services, Malawi Ministry of Health, Lilongwe, Malawi.
Vorster MhangoDepartment of Clinical Services, Malawi Ministry of Health, Lilongwe, Malawi.
Khumbo MbeweDepartment of Clinical Services, Malawi Ministry of Health, Lilongwe, Malawi.
Michael MelgarDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Michael OdoDepartment of HIV and AIDS, Malawi Ministry of Health, Lilongwe, Malawi.
Andreas JahnDepartment of HIV and AIDS, Malawi Ministry of Health, Lilongwe, Malawi.
Nicole BuonoDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Lilongwe, Malawi.
Alice MaidaDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Lilongwe, Malawi.
Belaineh GirmaNational Tuberculosis Control Program, Malawi Ministry of Health, Lilongwe, Malawi.
Thokozani KaluaDepartment of HIV and AIDS, Malawi Ministry of Health, Lilongwe, Malawi.
Rose NyirendaDepartment of HIV and AIDS, Malawi Ministry of Health, Lilongwe, Malawi.
Joram SungutiElizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
Godfrey WoelkElizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
Laurence J GundeDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Lilongwe, Malawi.
Tigest F MekonnenDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Lilongwe, Malawi.
Thulani MaphosaElizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
Evelyn J KimDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Lilongwe, Malawi.
Andrew F AuldDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Lilongwe, Malawi.
Adamson S MuulaSchool of Public Health and Family Medicine, Kamuzu University of Health Sciences, Blantyre, Malawi.
John E OeltmannDivision of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ministry of Health · MWCenters for Disease Control and Prevention · USElizabeth Glaser Pediatric AIDS Foundation · USPublic Health Institute of Malawi · MWKamuzu Central Hospital · MWKamuzu University of Health SciencesLighthouse Trust · MWMcKing Consulting (United States) · USNational Center for Chronic Disease Prevention and Health Promotion · USUniversity of Florida · US

Funding

CDC HHSIntramural CDC HHS CC999999PEPFAR
6 · The paper itself

Abstract

backgroundPellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash. Isoniazid disrupts intracellular niacin synthesis and might induce niacin deficiency. In 2017, Malawi scaled up continuous isoniazid preventive treatment (IPT) for tuberculosis prevention among people living with HIV. In addition, an under-diversified diet based on subsistence maize, as is commonly the case in Malawi, is a risk factor for pellagra. We aimed to investigate whether large-scale isoniazid exposure in Malawi contributed to the cumulative risk for pellagra in a nutritionally vulnerable population.

methodsWe did a matched case-control study to evaluate the association between daily, continuous isoniazid exposure and pellagra. We matched sequentially enrolled patients with pellagra each with four control participants by sex and age from referral dermatology centres in three IPT scale-up districts in Malawi (Lilongwe, Blantyre, and Zomba) to evaluate isoniazid as a risk for pellagra using multivariable conditional logistic regression. We established a community clinic referral system surrounding the dermatology clinic in each district to enhance case-finding and included all patients with pellagra, regardless of referral status. The primary outcome was dermatologist-diagnosed pellagra. We calculated the interval between isoniazid initiation and rash onset and assessed 30-day clinical outcomes after multi-B vitamin treatment containing 300 mg nicotinamide daily.

findingsBetween Feb 5 and Aug 9, 2019, we enrolled 197 patients with pellagra and 781 matched controls. Isoniazid exposure was associated with an increased risk of pellagra (adjusted odds ratio 42·6 [95% CI 13·3-136·6]). Significant covariates included HIV infection, referral status, food insecurity, underweight, excess alcohol consumption, and, among women, lactation. The median time from isoniazid initiation to rash onset was shorter during the season of food scarcity (5 months [IQR 3-7]) compared with the harvest season (9 months [8-11]; hazard ratio 7·2 [95% CI 3·2-16·2], log-rank p<0·0001). Those with isoniazid-associated pellagra who discontinued isoniazid and adhered to multi-B vitamin treatment showed 30-day clinical improvement.

interpretationContinuous IPT scale-up and the annual period of food scarcity both increased the risk of pellagra in Malawi. Use of shorter rifamycin-based regimens for tuberculosis prevention and food fortification in populations with undernutrition might reduce this risk. Niacin-containing multi-B vitamin co-administration with isoniazid as pellagra prevention is worth exploring further.

fundingThis study was supported by the President's Emergency Plan for AIDS Relief through the US Centers for Disease Control and Prevention under project 7173.

Indexed as

Antitubercular AgentsHIV InfectionsIsoniazidPellagraTuberculosisCase-Control StudiesExanthemaFemaleHumansMaleNiacinVitamin B ComplexAntitubercular AgentsIsoniazidNiacinVitamin B Complex

Identifiers

PMID35427527
PMCPMC11488830
OpenAlexW4223440787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.